# Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

> **NCT02546661** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 117 (actual)

## Conditions studied

- Muscle Invasive Bladder Cancer

## Interventions

- **DRUG:** AZD4547
- **DRUG:** MEDI4736
- **DRUG:** Olaparib
- **DRUG:** AZD1775
- **DRUG:** Vistusertib
- **DRUG:** AZD9150
- **DRUG:** Selumetinib

## Key facts

- **NCT ID:** NCT02546661
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-12-28
- **Primary completion:** 2020-03-18
- **Final completion:** 2026-01-30
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02546661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02546661, "Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02546661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*